Analyst Research

Report Title Price
Provider: ValuEngine, Inc.
$25.00
Provider: Finlabo SIM Spa
$10.00
Provider: Reuters Investment Profile
$20.00
Provider: Reuters Investment Profile
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Bayer AG’s Bayer HealthCare Initiates Xarelto Study in Patients with Non-Valvular Atrial Fibrillation Undergoing Percutaneous Coronary Intervention with Stent Placement


Friday, 8 Mar 2013 08:23am EST 

Bayer AG’s Bayer HealthCare announced the initiation of the PIONEER AF-PCI study, a Phase IIIb clinical study of its oral anticoagulant Xarelto (rivaroxaban) to investigate how best to treat patients with non-valvular atrial fibrillation (AF) who undergo percutaneous coronary intervention (PCI) with stent placement. The PIONEER AF-PCI study will enroll approximately 2,100 patients worldwide. The trial will assess the safety of two rivaroxaban treatment strategies and a dose-adjusted vitamin K antagonist (VKA) treatment strategy. Patients will be treated for 12 months. The PIONEER AF-PCI trial is part of the global clinical development program for rivaroxaban, which will - by the time of its completion – have involved more than 100,000 patients worldwide. 

Company Quote

98.71
-2.24 -2.22%
25 Jul 2014